Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Treatment Period 1 (double-blind, 52-week treatment period): In patients with moderate-to-severe asthma receiving SoC asthma therapy, to evaluate the long-term safety of QAW039 (150 mg once daily and 450 mg once daily), compared with placebo, as assessed by: -treatment emergent adverse events (AEs); -treatment emergent serious adverse events (SAEs); and -study discontinuations due to treatment emergent AEs. Treatment Period 1 and Treatment Period 2 combined: In patients with moderate-to-severe-asthma receiving SoC asthma therapy, to evaluate the long-term safety of QAW039 (150 mg once daily and 450 mg once daily), compared with placebo, as assessed by: -treatment emergent AEs -treatment emergent SAEs; and -study discontinuations due to treatment emergent AEs.
Critère d'inclusion
- Asthma